Radiopharm Theranostics Ltd. (RADX) said Tuesday it has signed a supply agreement with Siemens Healthineers for RAD101, a novel imaging small molecule targeting fatty acid synthase (FASN) to diagnose suspected recurrent brain metastases from solid tumors.
Under the agreement, Siemens Healthineers will manufacture and distribute Fluorine-18-labeled RAD101 to support Radiopharm's upcoming Phase 3 trial in the U.S.
Interim Phase 2b data showed significant and selective tumor uptake in brain metastases, with 90% concordance with MRI, meeting the primary endpoint.
The company's shares closed at $4.42 on Monday, up 0.45%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.